(Q40565585)

21 September 2017

Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes (English)

1 reference

21 September 2017

0 references

1 reference

1 reference

8

Andrew Raubitschek

0 references

author name string

Jinjuan Wang

1

1 reference

21 September 2017

Oliver W Press

2

1 reference

21 September 2017

Catherine G Lindgren

3

1 reference

21 September 2017

Philip Greenberg

4

1 reference

21 September 2017

Stanley Riddell

5

1 reference

21 September 2017

Xiaojun Qian

6

1 reference

21 September 2017

Christian Laugen

7

1 reference

21 September 2017

Andrew Raubitschek

8

1 reference

21 September 2017

Stephen J Forman

9

1 reference

21 September 2017

Michael C Jensen

10

1 reference

21 September 2017

1 April 2004

1 reference

21 September 2017

1 reference

21 September 2017

9

1 reference

21 September 2017

4

1 reference

21 September 2017

577-586

1 reference

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Rituximab: perspective on single agent experience, and future directions in combination trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Cell surface antigen and molecular targeting in the treatment of hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Adoptive T-cell therapy for the treatment of solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Clinical trials with CMV-specific T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Endowing T cells with antibody specificity using chimeric T cell receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Human T lymphocyte genetic modification with naked DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2003.12.011

10.1016/J.YMTHE.2003.12.011

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference